Nelly Mezzaroba, Sonia Zorzet, Erika Secco, Stefania Biffi, Claudio Tripodo, Marco Calvaruso, Ramiro Mendoza-Maldonado, Sara Capolla, Marilena Granzotto, Ruben Spretz, Gustavo Larsen, Sandra Noriega, Marianna Lucafò, Eduardo Mansilla, Chiara Garrovo, Gustavo H Marín, Gabriele Baj, Valter Gattei, Gabriele Pozzato, Luis Núñez, Paolo Macor
Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells...
2013: PloS One